Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of ...

Perioperative optimization of nutrition leads to lower risks, better outcomes, and improved quality of life for patients.

Agomab Therapeutics NV (‘Agomab’) today announced positive interim results from 44 patients completing treatment in the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal ...

AGMB-129 hit all primary and secondary endpoints in interim read-out from 44 patients after 12 weeks treatment -- -- Detailed interim STENOVA results to be presented at future scientific conference ...

The length of your entire digestive system from the mouth to the anus is approximately 30 feet long. Your digestive system is responsible for breaking down the foods you eat so that you can absorb ...